Home
Sign In
About
Curriculum
Activity Information
Target Audience
Learning Objectives
Technical Requirements
The Curriculum in Iron Metabolism & Related Disorders is supported by an educational grant from
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Course materials have been developed for use outside of the United States.
|
 |
|
|
|
|
|
Case 1 |
Case 2 |
Case 3 |
Case 4
|
Iron Overload Case Library, Case 2: Dose Titration in a Patient with Myelodysplastic Syndromes
The cornerstone of therapy in patients with myelodysplastic syndromes (MDS) is supportive care with blood transfusions. Many patients will live long enough to develop clinical consequences of iron overload, thus requiring chelation therapy. This case of an MDS patient examines the factors that go into determining appropriate candidates for iron chelation, as well as the use of dose titration and adjustments to manage suboptimal response to treatment and treatment-related side effects.
|
|
Faculty
|
|
|
Aristoteles A.N. Giagounidis, MD, PhD
St. Johannes Hospital
Medizinische Klinik II
Duisburg, Germany
|
|
|
Target Audience
This activity is designed for haematologists, medical oncologists, haematology-oncology specialists, and other healthcare professionals involved in the screening, evaluation, treatment, and management of adults and children with iron overload, resulting from the spectrum of chronic iron overload diseases.
|
Learning Objectives
After participating in this activity, participants should be better able to:
- Based on IPSS risk level and serum ferritin values, determine which patients with myelodysplastic syndromes are candidates for iron chelation therapy and assess the need for dose adjustments to manage side effects, maintain/reinstitute iron chelation therapy, and improve quality of life
|
Disclosure Information
Aristoteles A.N. Giagounidis, MD, PhD, is on the speakers bureau of Celgene Corporation; is on advisory boards for Novartis Pharmaceuticals Corporation and Pharmion Corporation; and is a stock shareholder in Hoffmann-La Roche Inc. Dr. Giagounidis has disclosed that he will not reference any unlabeled/unapproved uses of drugs or devices.
|
|
|
|
|
|
|
